L-dopa slows the progression of familial parkinsonism

The putative toxicity of levcodopa has long been debated. Loevodopa is the mainstay of therapy for Parkinson's disease. Sometimes treatment is delayed because of fear of toxicity.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1999-05, Vol.353 (9167), p.1850-1851
Main Authors: Gwinn-Hardy, Katrina, Evidente, Virgilio Gerald H, Waters, Cheryl, Muenter, Manfred D, Hardy, John
Format: Article
Language:English
Subjects:
Adult
Anticonvulsants. Antiepileptics. Antiparkinson agents
Antiparkinson Agents - therapeutic use
Antiparkinson Agents - toxicity
Biological and medical sciences
Disease Progression
Drug therapy
Humans
Levodopa - therapeutic use
Levodopa - toxicity
Medical research
Medical sciences
Middle Aged
Neuropharmacology
Parkinson Disease - drug therapy
Parkinson Disease - genetics
Parkinson Disease - mortality
Parkinson's disease
Pharmacology. Drug treatments
Survival Analysis
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c417t-ae0642b7d0f8b2b116f0a321168e7099f71d9746c1269a4a3fec0db66b957cfe3
cites cdi_FETCH-LOGICAL-c417t-ae0642b7d0f8b2b116f0a321168e7099f71d9746c1269a4a3fec0db66b957cfe3
container_end_page 1851
container_issue 9167
container_start_page 1850
container_title The Lancet (British edition)
container_volume 353
creator Gwinn-Hardy, Katrina
Evidente, Virgilio Gerald H
Waters, Cheryl
Muenter, Manfred D
Hardy, John
description The putative toxicity of levcodopa has long been debated. Loevodopa is the mainstay of therapy for Parkinson's disease. Sometimes treatment is delayed because of fear of toxicity.
doi_str_mv 10.1016/S0140-6736(99)01398-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_198994048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673699013987</els_id><sourcerecordid>42174037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-ae0642b7d0f8b2b116f0a321168e7099f71d9746c1269a4a3fec0db66b957cfe3</originalsourceid><addsrcrecordid>eNqFkEtLxDAUhYMozjj6E5QiLnRRvbdNk2YlMviCARcquAtpmmi0bcZkRvHf23mg7lydzXfPPXyE7COcIiA7uwekkDKes2MhTgBzUaZ8gwyRcpoWlD9tkuEPMiA7Mb4CAGVQbJMBQl4IinRIikla-6lKYuM_YzJ7Mck0-OdgYnS-S7xNrGpd41STTFV4c130nYvtLtmyqolmb50j8nh1-TC-SSd317fji0mqKfJZqgwwmlW8BltWWYXILKg867M0HISwHGvBKdOYMaGoyq3RUFeMVaLg2pp8RA5Xvf2o97mJM_nq56HrX0oUpRAUaNlDxQrSwccYjJXT4FoVviSCXLiSS1dyIUIKIZeuJO_vDtbl86o19Z-rlZweOFoDKmrV2KA67eIvx0WJDHvsfIWZ3sSHM0FG7UynTe2C0TNZe_fPkm8xCoSK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198994048</pqid></control><display><type>article</type><title>L-dopa slows the progression of familial parkinsonism</title><source>EBSCOhost Business Source Ultimate</source><source>ScienceDirect Journals</source><creator>Gwinn-Hardy, Katrina ; Evidente, Virgilio Gerald H ; Waters, Cheryl ; Muenter, Manfred D ; Hardy, John</creator><creatorcontrib>Gwinn-Hardy, Katrina ; Evidente, Virgilio Gerald H ; Waters, Cheryl ; Muenter, Manfred D ; Hardy, John</creatorcontrib><description>The putative toxicity of levcodopa has long been debated. Loevodopa is the mainstay of therapy for Parkinson's disease. Sometimes treatment is delayed because of fear of toxicity.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(99)01398-7</identifier><identifier>PMID: 10359414</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Adult ; Anticonvulsants. Antiepileptics. Antiparkinson agents ; Antiparkinson Agents - therapeutic use ; Antiparkinson Agents - toxicity ; Biological and medical sciences ; Disease Progression ; Drug therapy ; Humans ; Levodopa - therapeutic use ; Levodopa - toxicity ; Medical research ; Medical sciences ; Middle Aged ; Neuropharmacology ; Parkinson Disease - drug therapy ; Parkinson Disease - genetics ; Parkinson Disease - mortality ; Parkinson's disease ; Pharmacology. Drug treatments ; Survival Analysis ; Toxicity</subject><ispartof>The Lancet (British edition), 1999-05, Vol.353 (9167), p.1850-1851</ispartof><rights>1999 Elsevier Ltd</rights><rights>1999 INIST-CNRS</rights><rights>Copyright Lancet Ltd. May 29, 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-ae0642b7d0f8b2b116f0a321168e7099f71d9746c1269a4a3fec0db66b957cfe3</citedby><cites>FETCH-LOGICAL-c417t-ae0642b7d0f8b2b116f0a321168e7099f71d9746c1269a4a3fec0db66b957cfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1798161$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10359414$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gwinn-Hardy, Katrina</creatorcontrib><creatorcontrib>Evidente, Virgilio Gerald H</creatorcontrib><creatorcontrib>Waters, Cheryl</creatorcontrib><creatorcontrib>Muenter, Manfred D</creatorcontrib><creatorcontrib>Hardy, John</creatorcontrib><title>L-dopa slows the progression of familial parkinsonism</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>The putative toxicity of levcodopa has long been debated. Loevodopa is the mainstay of therapy for Parkinson's disease. Sometimes treatment is delayed because of fear of toxicity.</description><subject>Adult</subject><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Antiparkinson Agents - toxicity</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>Levodopa - therapeutic use</subject><subject>Levodopa - toxicity</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - genetics</subject><subject>Parkinson Disease - mortality</subject><subject>Parkinson's disease</subject><subject>Pharmacology. Drug treatments</subject><subject>Survival Analysis</subject><subject>Toxicity</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkEtLxDAUhYMozjj6E5QiLnRRvbdNk2YlMviCARcquAtpmmi0bcZkRvHf23mg7lydzXfPPXyE7COcIiA7uwekkDKes2MhTgBzUaZ8gwyRcpoWlD9tkuEPMiA7Mb4CAGVQbJMBQl4IinRIikla-6lKYuM_YzJ7Mck0-OdgYnS-S7xNrGpd41STTFV4c130nYvtLtmyqolmb50j8nh1-TC-SSd317fji0mqKfJZqgwwmlW8BltWWYXILKg867M0HISwHGvBKdOYMaGoyq3RUFeMVaLg2pp8RA5Xvf2o97mJM_nq56HrX0oUpRAUaNlDxQrSwccYjJXT4FoVviSCXLiSS1dyIUIKIZeuJO_vDtbl86o19Z-rlZweOFoDKmrV2KA67eIvx0WJDHvsfIWZ3sSHM0FG7UynTe2C0TNZe_fPkm8xCoSK</recordid><startdate>19990529</startdate><enddate>19990529</enddate><creator>Gwinn-Hardy, Katrina</creator><creator>Evidente, Virgilio Gerald H</creator><creator>Waters, Cheryl</creator><creator>Muenter, Manfred D</creator><creator>Hardy, John</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>19990529</creationdate><title>L-dopa slows the progression of familial parkinsonism</title><author>Gwinn-Hardy, Katrina ; Evidente, Virgilio Gerald H ; Waters, Cheryl ; Muenter, Manfred D ; Hardy, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-ae0642b7d0f8b2b116f0a321168e7099f71d9746c1269a4a3fec0db66b957cfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Antiparkinson Agents - toxicity</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>Levodopa - therapeutic use</topic><topic>Levodopa - toxicity</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - genetics</topic><topic>Parkinson Disease - mortality</topic><topic>Parkinson's disease</topic><topic>Pharmacology. Drug treatments</topic><topic>Survival Analysis</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gwinn-Hardy, Katrina</creatorcontrib><creatorcontrib>Evidente, Virgilio Gerald H</creatorcontrib><creatorcontrib>Waters, Cheryl</creatorcontrib><creatorcontrib>Muenter, Manfred D</creatorcontrib><creatorcontrib>Hardy, John</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gwinn-Hardy, Katrina</au><au>Evidente, Virgilio Gerald H</au><au>Waters, Cheryl</au><au>Muenter, Manfred D</au><au>Hardy, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>L-dopa slows the progression of familial parkinsonism</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1999-05-29</date><risdate>1999</risdate><volume>353</volume><issue>9167</issue><spage>1850</spage><epage>1851</epage><pages>1850-1851</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>The putative toxicity of levcodopa has long been debated. Loevodopa is the mainstay of therapy for Parkinson's disease. Sometimes treatment is delayed because of fear of toxicity.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>10359414</pmid><doi>10.1016/S0140-6736(99)01398-7</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 1999-05, Vol.353 (9167), p.1850-1851
issn 0140-6736
1474-547X
language eng
recordid cdi_proquest_journals_198994048
source EBSCOhost Business Source Ultimate; ScienceDirect Journals
subjects Adult
Anticonvulsants. Antiepileptics. Antiparkinson agents
Antiparkinson Agents - therapeutic use
Antiparkinson Agents - toxicity
Biological and medical sciences
Disease Progression
Drug therapy
Humans
Levodopa - therapeutic use
Levodopa - toxicity
Medical research
Medical sciences
Middle Aged
Neuropharmacology
Parkinson Disease - drug therapy
Parkinson Disease - genetics
Parkinson Disease - mortality
Parkinson's disease
Pharmacology. Drug treatments
Survival Analysis
Toxicity
title L-dopa slows the progression of familial parkinsonism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T15%3A25%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=L-dopa%20slows%20the%20progression%20of%20familial%20parkinsonism&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Gwinn-Hardy,%20Katrina&rft.date=1999-05-29&rft.volume=353&rft.issue=9167&rft.spage=1850&rft.epage=1851&rft.pages=1850-1851&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(99)01398-7&rft_dat=%3Cproquest_cross%3E42174037%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c417t-ae0642b7d0f8b2b116f0a321168e7099f71d9746c1269a4a3fec0db66b957cfe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=198994048&rft_id=info:pmid/10359414&rfr_iscdi=true